Sclerotherapy and foam sclerotherapy for varicose veins. 2009

P Coleridge Smith
The Bridge Clinic, Bridge Road, Maidenhead SL6 8DG, Berks, UK. p.coleridgesmith@ucl.ac.uk

OBJECTIVE To review published evidence concerning treatment of varicose veins using ultrasound-guided foam sclerotherapy (UGFS) to assess the safety and efficacy of this treatment. METHODS Medical literature databases including MedLine, Embase and DH-DATA were searched for recent literature concerning UGFS. Papers describing the early results and later outcome have been assessed and their main findings were included in this summary. RESULTS Few randomized studies have been published in this field and much of the available data come from clinical series reported by individual clinicians. It is clear that foam sclerotherapy is far more effective than liquid sclerotherapy and that ultrasound imaging allows the treatment to be delivered accurately to affected veins. There is evidence that 3% polidocanol foam is no more effective than 1% polidocanol foam. The optimum ratio of gas to liquid is 4:1, although a range of ratios is reported in the published work. There is a wide variation in the volume used as well as the method by which it is injected. The use of carbon dioxide foam reduces the systemic complications, particularly visual disturbance, as compared with air foams. Very few serious adverse events have been reported in the literature despite the widespread use of this method. Rates of recanalization of saphenous trunks following UGFS are similar to those observed after endovenous laser and endovenous RF ablation of veins, as well as the residual incompetence after surgical treatment. CONCLUSIONS UGFS is a safe and effective method of treating varicose veins. The relative advantages or disadvantages of this treatment in the longer term have yet to be published.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D011092 Polyethylene Glycols Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Macrogols,Polyoxyethylenes,Carbowax,Macrogol,Polyethylene Glycol,Polyethylene Oxide,Polyethyleneoxide,Polyglycol,Glycol, Polyethylene,Glycols, Polyethylene,Oxide, Polyethylene,Oxides, Polyethylene,Polyethylene Oxides,Polyethyleneoxides,Polyglycols,Polyoxyethylene
D002245 Carbon Dioxide A colorless, odorless gas that can be formed by the body and is necessary for the respiration cycle of plants and animals. Carbonic Anhydride,Anhydride, Carbonic,Dioxide, Carbon
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003902 Detergents Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. Cleansing Agents,Detergent Pods,Laundry Detergent Pods,Laundry Pods,Syndet,Synthetic Detergent,Agent, Cleansing,Agents, Cleansing,Cleansing Agent,Detergent,Detergent Pod,Detergent Pod, Laundry,Detergent Pods, Laundry,Detergent, Synthetic,Detergents, Synthetic,Laundry Detergent Pod,Laundry Pod,Pod, Detergent,Pod, Laundry,Pod, Laundry Detergent,Pods, Detergent,Pods, Laundry,Pods, Laundry Detergent,Synthetic Detergents
D004304 Dosage Forms Completed forms of the pharmaceutical preparation in which prescribed doses of medication are included. They are designed to resist action by gastric fluids, prevent vomiting and nausea, reduce or alleviate the undesirable taste and smells associated with oral administration, achieve a high concentration of drug at target site, or produce a delayed or long-acting drug effect. Dosage Form,Form, Dosage,Forms, Dosage
D004618 Embolism, Air Blocking of a blood vessel by air bubbles that enter the circulatory system, usually after TRAUMA; surgical procedures, or changes in atmospheric pressure. Air Embolism,Embolism, Gas,Air Embolisms,Embolisms, Air,Embolisms, Gas,Gas Embolism,Gas Embolisms
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077423 Polidocanol An alkyl polyglycol ether of LAURYL ALCOHOL, chemically defined as an alcohol ethoxylate having an average alkyl chain of 12–14 carbon atoms, and an ethylene oxide chain of 9 ethylene oxide units. It is used as a detergent, and medically as a local anesthetic, and as a sclerosing agent for the treatment of ESOPHAGEAL AND GASTRIC VARICES and VARICOSE VEINS. Aethoxysclerol,Aethoxysklerol,Aetoxisclerol,Atossisclerol,Atoxysclerol,Brij 30,Brij-30,Dodecyl Ethyleneglycol Monoether,Ethoxysclerol,Hydroxypolyethoxydodecane,Laureth,Laureth 9,Laureth-1,Laureth-4,Laureth-7,Laureth-9,Lauromacrogol,Lauromacrogol 400,Lauromacrogols,Lubrol 12A9,Lubrol-PX,Nonaethylene Glycol Monododecyl Ether,Nonaethyleneglycol Monododecyl Ether,Polyethylene Glycol Monododecyl Ether,Polyethylene Glycol-7-lauryl Ether,Polyoxyethylene 9-lauryl Ether,Polyoxyethylene Lauryl Ether,Polyoxyethylene(4) Lauryl Ether,Polyoxyethylene-4-dodecyl Ether,Polyoxyethylenedodecyl Ether,Tetraethylene Glycol Dodecyl Ether,Tetraethyleneglycol Lauryl Ether,Thesit,alpha-Dodecyl-omega-hydroxypoly(oxy-1,2ethanediyl),Brij30,Dodecyl Ethyleneglycol Monoethers,Ether, Nonaethyleneglycol Monododecyl,Ether, Polyethylene Glycol-7-lauryl,Ether, Polyoxyethylene 9-lauryl,Ether, Polyoxyethylene Lauryl,Ether, Polyoxyethylene-4-dodecyl,Ether, Tetraethyleneglycol Lauryl,Ethyleneglycol Monoether, Dodecyl,Laureth 1,Laureth 4,Laureth 7,Laureths,Lauryl Ether, Tetraethyleneglycol,Lubrol PX,Monododecyl Ether, Nonaethyleneglycol,Monoether, Dodecyl Ethyleneglycol,Nonaethyleneglycol Monododecyl Ethers,Polidocanols,Polyethylene Glycol 7 lauryl Ether,Polyethylene Glycol-7-lauryl Ethers,Polyoxyethylene 4 dodecyl Ether,Polyoxyethylene 9 lauryl Ether,Polyoxyethylene 9-lauryl Ethers,Polyoxyethylene Lauryl Ethers,Polyoxyethylenedodecyl Ethers,Tetraethyleneglycol Lauryl Ethers

Related Publications

P Coleridge Smith
December 2016, Revue medicale suisse,
P Coleridge Smith
August 2007, The British journal of surgery,
P Coleridge Smith
January 2007, Vascular,
P Coleridge Smith
January 2020, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
P Coleridge Smith
April 2018, The Surgical clinics of North America,
P Coleridge Smith
April 2008, The New England journal of medicine,
P Coleridge Smith
June 2011, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery,
P Coleridge Smith
April 2011, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],
P Coleridge Smith
August 2006, The British journal of surgery,
Copied contents to your clipboard!